

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 February 2008 (07.02.2008)

PCT

(10) International Publication Number  
**WO 2008/015695 A2**

- (51) **International Patent Classification:**  
A61K 47/40 (2006.01) A61K 31/335 (2006.01)
- (21) **International Application Number:**  
PCT/IN2007/000199
- (22) **International Filing Date:** 15 May 2007 (15.05.2007)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
748/MUM/2006 15 May 2006 (15.05.2006) IN

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) **Applicant** (*for all designated States except US*): **SUN PHARMACEUTICAL INDUSTRIES LIMITED** [IN/IN]; Acme Plaza, Andheri-Kurla Road, Andheri (e), Mumbai 400 059 (IN).

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- (72) **Inventors; and**
- (75) **Inventors/Applicants** (*for US only*): **BHOWMICK, Subhas, Balaram** [IN/IN]; Sun Pharma Advanced Research Centre, Nima Compound, Near Pratham Enclave, Tandalja Road, Baroda 390 020 (IN). **LADDHA, Ritu, Nitin** [IN/IN]; Sun Pharma Advanced Research Centre, Nima Compound, Near Pratham Enclave, Tandalja Road, Baroda 390 020 (IN). **KHOPADE, Surekha** [IN/IN]; Sun Pharma Advanced Research Centre, Nima Compound, Near Pratham Enclave, Tandalja Road, Baroda 390 020 (IN).

**Declarations under Rule 4.17:**

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *without international search report and to be republished upon receipt of that report*

(54) **Title:** INCLUSION COMPLEX

(57) **Abstract:** The invention relates to an inclusion complex of olopatadine or its pharmaceutically acceptable salt and hydroxyalkyl-β-cyclodextrin, preferably hydroxypropyl-β-cyclodextrin. The present invention also relates to an aqueous topical solution comprising a therapeutically effective amount of olopatadine or its pharmaceutically acceptable salt; hydroxyalkyl-β-cyclodextrin, preferably hydroxypropyl-β-cyclodextrin and hydroxypropyl methylcellulose in an amount sufficient to enhance the physical stability of the solution.



WO 2008/015695 A2

## INCLUSION COMPLEX

### FIELD OF THE INVENTION

5 The present invention relates to inclusion complex of olopatadine in cyclodextrin and to aqueous solutions of olopatadine or its pharmaceutically acceptable salt for topical administration and process for preparation thereof.

### BACKGROUND OF THE INVENTION

10

Olopatadine hydrochloride is a carboxylic acid derivative of doxepin, chemically described as (Z)-11-[3-(Dimethylamino) propylidene]-6,11-dihydrodibenz [b,e]oxepin-2-acetic acid hydrochloride [C<sub>21</sub>H<sub>23</sub> NO<sub>3</sub> .HCl], as disclosed in U.S. Pat Nos.4,871,865 and 4,923,892, both assigned to Burroughs Wellcome. Olopatadine has antihistaminic and antiasthmatic activity.

15

Olopatadine hydrochloride is commercially available in the U.S as 0.1% and 0.2% sterile ophthalmic solutions under the brand names PATANOL<sup>®</sup> and PATADAY<sup>®</sup> respectively, both marketed by Alcon. PATANOL<sup>®</sup> is indicated for the treatment of signs and symptoms of allergic conjunctivitis and the approved ophthalmic solution contains olopatadine hydrochloride equivalent to 0.1% olopatadine, 0.01% benzalkonium chloride as preservative, dibasic sodium phosphate, sodium chloride, hydrochloric acid and / or sodium hydroxide (to adjust the pH) and purified water. It has a pH of about 7, and osmolality of about 300mOsm/kg. PATADAY<sup>®</sup> is indicated for the treatment of ocular itching associated with allergic conjunctivitis and the approved ophthalmic solution contains olopatadine hydrochloride equivalent to 0.2%  
20 olopatadine, 0.01% benzalkonium chloride as preservative, povidone, dibasic sodium phosphate, sodium chloride, edetate disodium, hydrochloric acid and / or sodium hydroxide (to adjust the  
25 pH) and purified water. It has a pH of about 7, and osmolality of about 300mOsm/kg.

One obstacle for preparing olopatadine hydrochloride aqueous solutions for topical delivery is  
30 the stability of the aqueous solutions of olopatadine hydrochloride over the storage period. Olopatadine aqueous solutions having a concentrations of 0.17%w/v or higher were found to be

unstable over extended storage periods. The olopatadine hydrochloride precipitates or crystallizes out of the solution when used in concentrations higher than 0.17%w/v. Hence, there is a need for preparing aqueous solutions of olopatadine hydrochloride containing olopatadine in concentrations of about 0.17%w/v or greater, which are stable when stored over the shelf life of the product.

United States Patent No.6,995,186 (Alcon Inc., 2006, the '186 patent) discloses topically administrable solution composition for treating allergic or inflammatory disorders of the eye and nose comprising olopatadine and a polymeric ingredient, where the polymeric ingredient is a polymeric physical stability enhancing ingredient consisting essentially of polyvinylpyrrolidone or polystyrene sulfonic acid in an amount sufficient to enhance the physical stability of the solution, and wherein the composition does not contain polyvinyl alcohol, polyvinyl acrylic acid, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, xanthan gum. Polyvinyl alcohol, polyvinyl acrylic acid, hydroxypropyl methylcellulose, sodium carboxy methyl cellulose and xanthan gum have been disclosed in the '186 patent to cause physical instability of olopatadine solutions.

In order to overcome the physical stability problems associated with olopatadine aqueous solutions, we have tried various ingredients selected from hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD), polysorbate 20, polysorbate 80, propylene glycol, hydroxypropyl methylcellulose 2910 (HPMC E4M premium), polyvinylpyrrolidone K-30, xanthan gum, sodium carboxymethylcellulose (Sodium CMC), carbopol 934P, polyvinyl alcohol and mixtures thereof.

We have now surprisingly found that stable aqueous topical solutions of olopatadine hydrochloride can be prepared by forming an inclusion complex with a hydroxyalkyl clodextrin, preferably hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD). Optionally, hydroxypropyl methylcellulose (HPMC) may be used to stabilize the inclusion complex in the pharmaceutical composition.

30

## SUMMARY OF THE INVENTION

5 In one aspect of the invention, there is provided an inclusion complex of olopatadine or its pharmaceutically acceptable salt and a hydroxyalkyl cyclodextrin, preferably hydroxypropyl- $\beta$ -cyclodextrin.

10 In another aspect of the invention, there is provided an aqueous topical solution comprising a therapeutically effective amount of olopatadine or its pharmaceutically acceptable salt; hydroxyalkyl  $\beta$ -cyclodextrin, preferably hydroxypropyl  $\beta$ -cyclodextrin and hydroxypropyl methyl cellulose in amount sufficient to enhance the physical stability of the solution.

## DETAILED DESCRIPTION OF THE INVENTION

15 The present invention provides an inclusion complex of olopatadine or its pharmaceutically acceptable salt and hydroxyalkyl- $\beta$ -cyclodextrin, particularly hydroxypropyl- $\beta$ -cyclodextrin. The present invention also provides an aqueous topical solution, comprising a therapeutically effective amount of olopatadine or its pharmaceutically acceptable salt; hydroxyalkyl- $\beta$ -cyclodextrin, particularly hydroxypropyl- $\beta$ -cyclodextrin and hydroxypropyl methylcellulose in  
20 an amount sufficient to enhance the physical stability of the solution.

Unless indicated otherwise, all component concentrations are presented on a %(w/v) basis and all reference to olopatadine are to olopatadine free base.

25 The term “in an amount sufficient to enhance the physical stability of the solution”, as used herein means that the amount of hydroxyalkyl- $\beta$ -cyclodextrin, particularly hydroxypropyl- $\beta$ -cyclodextrin is sufficient to form a complex with olopatadine or its pharmaceutically acceptable salt and thus keep it in solution, i.e. Prevent its precipitation or crystallization.

According to one embodiment of the present invention, the aqueous topical solution contains olopatadine or its pharmaceutically acceptable salts. Examples of the pharmaceutically acceptable salts of olopatadine include inorganic acid salts such as hydrochloride, hydrobromide, sulfate and phosphate; organic acid salts such as acetate, maleate, fumarate, tartrate and citrate; 5 alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as magnesium salt and calcium salt; metal salts such as aluminum salt and zinc salt; and organic amine addition salts such as triethylamine addition salt (also known as tromethamine), morpholine addition salt and piperidine addition salt. In a preferred embodiment of the present invention, the olopatadine for use in the aqueous topical solution is a hydrochloride salt. In a 10 most preferred embodiment of the present invention, the olopatadine hydrochloride salt may be used in concentrations such that it is equivalent to the olopatadine free base in amount ranging from about 0.17% to about 0.62%. Preferably, the solution formulations intended for use in the eye contain about 0.17% to about 0.25% olopatadine and the solution formulations intended for use in the nose contain about 0.35% to about 0.62% olopatadine.

15 According to one embodiment of the present invention, the aqueous topical solution comprises cyclodextrin to enhance the physical stability of the solution. Cyclodextrins are a group of structurally related saccharides which are formed by enzymatic cyclization of starch by a group of amylases termed glycosyltransferases. Cyclodextrins are cyclic oligosaccharides, consisting of 20 (alpha-1,4)-linked alpha-D-glucopyranose units, with a lipophilic central cavity and a hydrophilic outer surface. In aqueous solutions, cyclodextrins form inclusion complexes with many drugs through a process in which the water molecules located in the central cavity are replaced by either the whole drug molecule, or more frequently, by some lipophilic portion of the drug structure. Once included in the cyclodextrin cavity, the drug molecules may be dissociated 25 through complex dilution, by replacement of the included drug by some other suitable molecule or, the drug may be transferred to the matrix for which it has the highest affinity. Importantly, since no covalent bonds are formed or broken during the drug-cyclodextrin complex formation, the complexes are in dynamic equilibrium with free drug and cyclodextrin molecules. In solution, the complexes are usually prepared by addition of an excess amount of the drug to an aqueous 30 cyclodextrin solution. The most common naturally occurring cyclodextrins are alpha-

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.